January 2022 - Page 2 of 4 - BioMedWire (BMW)

MondayJan 24, 2022 1:21 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Commence Rollout of Their Miboko Application; Company Targets Employers & Insurers to Ensure Broad Commercial Distribution

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently announced the rollout of its Miboko application by targeting insurers and employers In 2019, over $760 billion was spent on diabetes-related health care, equating to $9,000 per diabetic patient compared to $1,600 for a non-diabetic individual The Miboko application provides users with an efficient and accurate means of tracking their day-to-day glycaemic levels, a key determinant of overall metabolic health Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs,…

MondayJan 24, 2022 12:30 pm

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices

Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapy The products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support The planned launch follows an amendment to federal regulations allowing physicians to request and prescribe restricted drugs for treatment-resistant patients Canada began the year on a high note by updating the Special Access Program (“SAP”), a move that demonstrates the government’s serious consideration of the…

MondayJan 24, 2022 9:30 am

Four Major Healthcare Tech Trends to Look for This Year

Many technology companies have used their expertise to solve issues caused by the coronavirus pandemic over the last two years, with healthcare companies also shifting their focus to technology and its potential to change how products and services are delivered. The global pandemic has sped up the digitization of the healthcare industry, with data from HIMSS Future of Healthcare Report showing that more than 75% of healthcare providers plan to increase their investment in digital solutions and technology over the next five years. This means that we will see growth in many areas, including wearables, genomics, personalized medicine and telemedicine,…

FridayJan 21, 2022 9:30 am

Exploring the Link Between OCD and Depression

Obsessive compulsive disorder (“OCD”) is characterized by excessive thoughts that cause compulsive behaviors while depression is a mental health disorder characterized by a loss of interest in daily activities and a constant depressed mood.Estimates from the International OCD Foundation show that roughly 25–50% of individuals with obsessive-compulsive disorder will also experience depression. Most individuals usually experience symptoms of obsessive compulsive disorder first. However, the conditions can begin at the same time for a small number. Can depression lead to OCD and vice versa? Data from the National Institute of Mental Health shows that compulsive disorder can be caused by childhood…

ThursdayJan 20, 2022 1:20 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Firmly Positioned in Growing Diabetes Tech Market With Recent CGM Shipment to UK Licensee

Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitor Company recently completed initial shipment to UK licensee While most medical technology businesses faced COVID-19-related restrictions (https://ibn.fm/NJbOa), Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for diabetes management, is favorably positioned in the rapidly growing diabetes tech…

ThursdayJan 20, 2022 9:30 am

Study Finds That New Lung Cancer Screening Guidelines Increase Eligibility for Black Women

A new study conducted by researchers from the University of California-Berkeley, the Northeastern University and Boston University has found that the new screening guidelines for lung cancer have significantly grown the eligibility of Black women. The U.S. Preventative Services Taskforce, which is made up of experts in evidence-based and preventative medicine, changed the lung cancer screening guidelines in April 2021 by reducing the required smoking “pack-years” to 20 from 30 and lowering the screening age of eligibility to 50, from 55. According to a research letter recently published in “JAMA Oncology,” these changes were made in order to increase the…

WednesdayJan 19, 2022 9:30 am

Study Suggests HIV Drugs Could Have Place in Brain Cancer Treatment

A new study conducted by researchers at the Brain Tumor Research Center at the University of Plymouth has found that the drugs used to treat HIV and AIDS may be effective in the treatment of low-grade brain tumors. The study’s researchers believe that ARVs could be prescribed for patients who have been diagnosed with acoustic neuroma and meningioma brain tumors, which often grow back after radiotherapy and surgery. Meningioma is a common primary tumor that may become cancerous as time goes by. This tumor develops from cells found in the meninges, which protect the spinal cord and the brain. On…

WednesdayJan 19, 2022 9:00 am

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap…

WednesdayJan 19, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

Company marked host of major milestones and accomplishments in 2021 Approvals, licenses, expansions and growth all essential pieces of Cybin success CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022 As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022. "2021 was an exciting year for Cybin,” said Cybin CEO…

TuesdayJan 18, 2022 9:30 am

AI Could Help Relieve Physician Stress

A report recently released by Medscape shows that more than 40% of physicians in the United States suffer from burnout. Burnout not only affects individuals emotionally but also impacts finances negatively, with data from the American Medical Association showing that burnout costs healthcare organizations $500,000 to $1 million per physician. The cost of burnout also includes indirect costs such as decreased patient satisfaction, lost patient care revenue, higher risk of malpractice suits, medical errors and damage to the reputation of the healthcare organization. The pandemic has only made things worse, with stress becoming a severe issue for doctors these last…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: January 2022

Nemaura Medical Inc. (NASDAQ: NMRD) Commence Rollout of Their Miboko Application; Company Targets Employers & Insurers to Ensure Broad Commercial Distribution

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices

Four Major Healthcare Tech Trends to Look for This Year

Exploring the Link Between OCD and Depression

Nemaura Medical Inc. (NASDAQ: NMRD) Firmly Positioned in Growing Diabetes Tech Market With Recent CGM Shipment to UK Licensee

Study Finds That New Lung Cancer Screening Guidelines Increase Eligibility for Black Women

Study Suggests HIV Drugs Could Have Place in Brain Cancer Treatment

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

AI Could Help Relieve Physician Stress

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search